Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3445 - Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program.

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Melanoma

Presenters

Bernardo Rapoport

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

B. Rapoport1, D. Vorobiof2, L. Dreosti3, A. Nosworthy4, G. Mcadam5, A. Jordaan6, M. De Necker7, J. De Beer8, H. Duvenhage9

Author affiliations

  • 1 Medical Oncology, The Medical Oncology Centre of Rosebank, 2196 - Johannesburg/ZA
  • 2 Oncology, Sandton Oncology Centre, 2199 - Sandton/ZA
  • 3 Oncology, Pretoria Academic Hospital, 1 - Pretoria/ZA
  • 4 Oncology, University of Witwatersrand Medical School, 2193 - Johannesburg/ZA
  • 5 Oncology, GVI Oncology, 7530 - Cape Town/ZA
  • 6 Oncology, Westridge Medical Centre, 4000 - Durban/ZA
  • 7 Data Services, TCD Outcomes Research, 0157 - Pretoria/ZA
  • 8 Data Services, TCD Outcomes Research, 0157 - Centurion/ZA
  • 9 Head Of Medical, BMS, 2191 - Woodmead/ZA
More

Resources

Abstract 3445

Background

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of patients with advanced pretreated melanoma. In 2015, a retrospective, multi-centre, non-interventional analysis was performed on data collected from the ipilimumab expanded access programme in South Africa, with last follow-up date (or death) in December 2014. The current study extends this analysis by follow-up on the long-term survival of pre-treated metastatic patients up to September 2016.

Methods

Follow-up questions were sent to participating investigators, who had patients who were still alive (29) or for whom it was not known whether they were still alive (11) following the last ipilimumab infusion. Investigators had to confirm whether patients were still alive, the date of death or last contact, clinical response at last contact, and whether the patient was still responding to ipilimumab.

Results

Of the 108 patients, 84 (78%) had cutaneous melanoma and 24 patients (22%) had non-cutaneous melanoma, including uveal, mucosal, and melanoma of unknown primary. Twenty patients previously received two or more lines of treatment for metastatic melanoma. The median age was 59 years (range 27 – 86) and there were 73 (68%) males and 35 (32%) females. Baseline ECOG PS was 0 in 33%, PS 1 in 58% and PS 2 in 6% of patients. The longest follow-up time available was 5.4 years. The median OS was 9.36 months (95% CI 7.48 – 11.84). One-year survival was 39% (95% CI 29% - 48%), 2-year survival was 22% (95% CI 15% - 30%), 3-year survival was 19% (95% CI 12% - 27%), 4- and 5-year survival was 15% (95% CI 8% - 21%). In the group of cutaneous melanoma patients, the 4- and 5-year survival was 17% (95% CI 9% - 25%) while in the non-cutaneous group the 4- and 5-year survival was 6% (95% CI 0% - 16%).

Conclusions

Ipilimumab at a dose of 3mg/kg is an effective treatment for patients with pre-treated advanced (unresectable or metastatic) melanoma and is associated with durable remissions and long-term survival.

Clinical trial identification

Protocol number: CA184-515 Ethics approval extended on protocol REC 2/21/05/14

Legal entity responsible for the study

Dr Bernardo L Rapoport

Funding

Investigator Sponsored Research (ISR) trough Bristol-Myers Squibb

Disclosure

H. Duvenhage: Head of Medical at Bristol-Myers Squibb All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.